Dr. Sheets is the founding CEO/board member of SeQure Dx. Prior to SeQure Dx, Dr. Sheets was at Mass General Brigham Venture as an entrepreneur in residence (EIR). Prior to her EIR, she was CMO/CEO/President of CSA Medical, where she oversaw the development of their innovative cryotherapy treatment device for chronic bronchitis. She entered industry at Cytyc Corp/HOLOGIC from 2002-2008 where she oversaw clinical trials, business units, supported business development ultimately rising to SVP/Chief Medical Officer. Her first venture company was Predictive Biosciences as GM/Chief Medical Officer where she developed Predictive’s flagship bladder cancer detection assay. In 2010, she joined QIAGEN as Chief Medical Officer/Vice President of North American R&D at QIAGEN, Inc. and led their IVD business team overseeing product development, sales/marketing, and led development of companion diagnostics for cancer treatment and various instrument platforms.
Prior to entering industry in 2002, Dr. Sheets was an associate professor, gynecologic oncology, at Brigham and Women’s Hospital/Harvard Medical School where her research centered on cervical cancer in conjunction with the Massachusetts Institute of Technology Spectroscopy Laboratory. She served on the NCI Gynecologic Cancer Steering Committee, the National Cancer Center Network and FDA/NIH advisory groups as well as consulting for numerous biomedical firms.